Experimental drug aims to tackle both obesity and knee arthritis
NCT ID NCT07709910
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This phase 3 trial tests an injectable drug called ribupatide in people who have both obesity and knee osteoarthritis. The study measures whether ribupatide can reduce knee pain and stiffness, improve joint function, and help with weight loss over 68 weeks. Participants are randomly assigned to receive ribupatide or a placebo, and neither they nor their doctors know which they receive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental injectable drug called ribupatide
- What this could lead to
- If successful, ribupatide could offer a new treatment that helps with both weight loss and knee pain in people with obesity and knee osteoarthritis.
- What could go wrong
- This is a phase 3 trial, but results may not confirm benefit or safety for everyone. Side effects are possible, and the drug may not work better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, 200233, China
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Can a new drug boost Semaglutide's power against diabetes and obesity?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- A daily pill for obesity? zenagamtide faces its biggest test yet.
- Dance and walking may boost heart health in obesity — a trial puts it to the test